In tableting operations for high-dose veterinary boluses and standard oral tablets, the drug substance designated Baojian Bolus Veterinary Grade API is first screened through a 500 µm sieve before being pre-blended with a direct-compression vehicle or granulated intermediate. Pre-blending uses a 1:10 geometric dilution to preserve content uniformity when the label claim is low and the unit mass is small; for higher unit doses, the active is triturated with the carrier in a 100 L V-blender. The final blend is compressed on a 16-station rotary tablet press equipped with a gravity feed frame. Compression force is adjusted to produce friability values not more than 1.0% under USP <1216> and disintegration times not more than 15 min in water at 37 °C under USP <701>. Content uniformity is evaluated with USP <905> using an acceptance value of AV ≤ 15.0 for the first 10 units. For ruminant bolus formats, elongated punches generate a scored unit for balling-gun administration; published data for this specific API at unit masses above 10 g is limited, so pilot-scale tooling trials and esophageal transit studies are required before scale-up. The finished tablets are film-coated only if the coating dispersion does not delay disintegration beyond the compendial limit. Humidity controls are required above 60% RH, and the granulate is re-dried if moisture uptake exceeds 0.5% w/w during compression.

Why Does Wet Granulation Dominate High-Dose Veterinary Tablet Production?

The choice of wet granulation over direct compression is driven by the need to control poor flow, low bulk density, and segregation at active loadings above 30% w/w. A top-spray fluid-bed granulator with inlet air temperature between 50–70 °C applies a binder solution prepared from povidone K30 or hydroxypropylmethylcellulose at 2.0–5.0% w/w of dry granulate. Granulation end-point is monitored by exhaust temperature and by loss on drying under USP <921>, with moisture content held below the limit established in the stability dossier, typically not more than 2.5% for milled granules. Dried granules are passed through a conical mill fitted with a 0.8–1.5 mm screen. Milled granules are blended with croscarmellose sodium at 2.0–4.0% w/w and magnesium stearate at 0.5–1.5% w/w; the lubricant is added last and mixed for no longer than 5 min to prevent hydrophobic film formation on granule surfaces. Dissolution is tested by USP <711> using S1/S2/S3 criteria from the approved monograph. This wet-granulation route also reduces dust exposure and improves operator safety, but the thermal step requires forced degradation data to confirm that the API remains stable at the selected inlet temperature. If the API is heat-labile, roller compaction against screens of 0.5–1.0 mm is a dry alternative, though published data for this specific API under roller compaction is limited.

Encapsulation of the veterinary-grade API into hard gelatin or HPMC capsules requires control of moisture transfer between the powder blend and the shell. The granulated or dry-blended material is filled on an intermittent-motion capsule filler with dosator or tamping-pin stations; fill weight is verified by net weight checks at intervals of 30 min during the batch. Content uniformity is measured by USP <905>, and dissolution by USP <711>. Hard gelatin capsule shells normally contain moisture between 13–16% w/w, so a blend with moisture above 4.0% or hygroscopicity above 60% RH can cause cap cracking or powder clumping. Pre-drying is therefore required when the API shows moisture uptake of more than 0.5% w/w in a 60% RH desiccator after 24 h. Sorption isotherms are generated according to Ph. Eur. 2.2.32 before fill release. If the active is moisture-sensitive, desiccant canisters are inserted into HDPE packs, and the closure is checked for ingress under USP <671>. The capsule fill blend should not contain reactive reducing sugars if the API has a primary amine, because Maillard browning can occur; forced degradation screening at 40 °C and 75% RH for 4 weeks is used to rule out this incompatibility before pivotal stability batches are produced.

Injectable Solution Sterility Assurance and Endotoxin Control

Terminal sterilization validation for injectable dosage forms requires the API to be dissolved or suspended in Water for Injection, then filled into depyrogenated glass vials or sterile flexible containers. The formulation is adjusted to an isotonic range of 250–350 mOsm/kg and a pH between 3.0–8.5 unless solubility or stability data impose narrower limits. The solution is sterilized by moist heat at 121 °C for 15 min unless the degradation rate requires an aseptic process with an F0 below 15 min; the chosen cycle is qualified with biological indicators according to USP <1229.2>. Particulate matter is controlled by USP <788>, with small-volume parenterals allowed no more than 6000 particles at or above 10 µm and no more than 600 particles at or above 25 µm per container. Bacterial endotoxins are tested by USP <85> or Ph. Eur. 2.6.14; the limit is calculated from the maximum dose per kg of body mass per hour for the target species. The drug substance specification must address residual solvents and elemental impurities, because trace elements can interact with rubber closures and glass surfaces. Filling lines use CIP/SIP sterilization, and dead-leg design is eliminated to prevent biofilm development. The finished injection is stored under refrigeration if forced degradation data show more than 5.0% assay loss at 40 °C after 6 months.

When Premix Carriers Shift from Rice Hulls to Calcium Carbonate

A switch from organic carrier hulls to inorganic calcium carbonate alters bulk density, dust extraction requirements, and API adsorption characteristics. The veterinary-grade API is first diluted as a 1:10 or 1:100 premix onto a carrier such as ground corn cob, rice hulls, or calcium carbonate, depending on the target feed form and the intended final concentration per tonne of complete feed. Carrier selection changes particle-size distribution and surface adsorption, so blend uniformity is checked by sampling from 10 locations in a 500 L ribbon mixer using a thief sampler and analyzing triplicate portions by HPLC or UV. Acceptance for premixes is based on a relative standard deviation not more than 5.0% RSD and a mean assay within 90.0–110.0% of label claim. Medicated feed premix operations in the United States are subject to FDA 21 CFR 225 cGMP and, when the substance is a veterinary feed directive drug, 21 CFR 558. In export flows, FAMI-QS certification and ISO 22000 feed safety management systems provide evidence of control. Carriers with bulk density below 0.4 g/cm³ segregate during pneumatic transfer, so screw conveyors or bucket elevators are preferred over air conveyors. Dust extraction at weighing and bagging stations uses high-efficiency media rated at 0.5 µm filtration.

Medicated feed powders and granules demand tighter blend uniformity than the solid dosage forms

Blending of medicated powders and granules for feed or drinking water is controlled by the same homogeneity principles as solid oral dosage manufacturing, but larger batch sizes and carrier variability introduce additional segregation risk. The API is mixed with lactose monohydrate, dextrose, or maltodextrin in a ribbon blender or double-cone blender; a two-step process comprises a high-shear pre-blend of the active with a 1:10 diluent ratio, followed by a low-shear final blend to achieve the label claim per gram. The final blend is sampled at 10 time points during mixing, and the mean assay must lie within 90.0–110.0% of label claim, with an RSD of not more than 5.0%. Finished powders and granules are tested for nonsterile microbial quality under USP <61> and USP <62>; oral preparations typically require a total aerobic microbial count not exceeding 1000 CFU/g and a total combined yeasts and molds count not exceeding 100 CFU/g. Specified organisms such as E. coli and Salmonella species must be absent. Packaging in multi-wall paper bags with an inner polyethylene liner is standard, and moisture barrier is verified by water vapor transmission rate testing under ASTM F1249. If the powder is intended for reconstitution in drinking water, a water-soluble carrier such as citric acid or sodium bicarbonate is included at a ratio that achieves the required final concentration in ppm in drinking water; the exact ratio is derived from the target species daily water intake and the approved dose per kg of body mass.

For oral solution and drench formulations, the API is dissolved or suspended in purified water; cosolvents such as propylene glycol or glycerin are added when the API concentration exceeds its aqueous solubility limit. The solution is prepared in a jacketed stainless steel vessel with a high-shear mixer, and pH is adjusted with hydrochloric acid or sodium hydroxide to a value that balances chemical stability and palatability. Antimicrobial preservation is validated for multi-dose oral preparations according to USP <51>; sodium benzoate at 0.05–0.1% w/v or potassium sorbate at 0.1–0.2% w/v is selected based on the challenge test and final pH. Oxidative degradation is controlled by nitrogen sparging and light-protective amber HDPE or glass packaging if forced oxidation studies demonstrate assay loss greater than 2.0% under peroxide stress. The finished solution is filtered through a 1–5 µm depth filter before filling, and container closure integrity is verified by USP <1207> or Ph. Eur. 3.2.9. Storage below 25 °C is evaluated under the stability protocol, but the assigned shelf life must be supported by data generated according to VICH GL 5. Compatibility with common proportioner pumps and dosing guns is evaluated by recirculation trials over 48 h, because precipitation in the dosing line is a known failure mode in swine and poultry operations. The API should not be combined with strong oxidizing agents unless forced degradation data demonstrate chemical compatibility.